Aduro Biotech (ADRO) to Acquire BioNovion in EUR 29M Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Leerink Partners Remains Bullish on Aduro Biotech (ADRO) Following Announced BioNovion Acquisition
September 25, 2015 9:04 AM EDTLeerink Partners reiterated an Outperform rating and $48.00 price target on Aduro Biotech (NASDAQ: ADRO) following announced acquisition of BioNovion. Analyst Seamus Fernandez views the acquisition as a strong strategic move.
Fernandez commented, "We view ADROs announced acquisition of privately held... More
